11-Sep-2026
No headlines found.
Immunocore to present at upcoming investor conferences
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Immunocore reports second quarter financial results and provides a business update
Globe Newswire (Thu, 6-Aug 7:00 AM ET)
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Globe Newswire (Thu, 30-Jul 7:00 AM ET)
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Immunocore Holdings PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol IMCR.
As of September 11, 2026, IMCR stock price declined to $32.60 with 292,938 million shares trading.
IMCR has a beta of 0.20, meaning it tends to be less sensitive to market movements. IMCR has a correlation of 0.01 to the broad based SPY ETF.
IMCR has a market cap of $1.68 billion. This is considered a Small Cap stock.
Last quarter Immunocore Holdings PLC - American Depositary Shares reported $116 million in Revenue and -$.02 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$.04.
In the last 3 years, IMCR traded as high as $76.98 and as low as $23.15.
The top ETF exchange traded funds that IMCR belongs to (by Net Assets): SPDW, BBP, CANC, GWX, ONEQ.
IMCR has underperformed the market in the last year with a price return of -10.9% while the SPY ETF gained +17.4%. However, in the short term, IMCR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +13.9% vs +3.9% return in SPY. But in the last 2 weeks, IMCR shares have been beat by the market, returning -11.0% compared to an SPY return of -0.7%.
IMCR support price is $32.85 and resistance is $34.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMCR shares will trade within this expected range on the day.